Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glycopyrrolate + dexmedetomidine
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination of glycopyrrolate, an anticholinergic agent, and dexmedetomidine, a selective alpha-2 adrenergic receptor agonist. This combination is used primarily in anesthesia settings where dexmedetomidine provides sedation, anxiolysis, and analgesia with minimal respiratory depression, while glycopyrrolate counteracts the bradycardia and hypotension commonly associated with dexmedetomidine.
02
Targets
ADRA2A (α2A)
Beyond the preview
Go deeper on glycopyrrolate + dexmedetomidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glycopyrrolate + dexmedetomidine.